☆ 4.4 Article

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations

JCO PRECISION ONCOLOGY (2020)

Get Full Text
Add to Collection

Journal

JCO PRECISION ONCOLOGY
Volume 4, Issue -, Pages 341-347

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/PO.19.00401

Keywords

-

Categories

Oncology

Funding

  1. Loxo Oncology (Stamford, CT)
  2. Cannonball Kids' Cancer
  3. National Cancer Institute [K12CA184746, P30CA008748]
  4. American Lebanese Syrian Associated Charities

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.